{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:50:19Z","timestamp":1790884219645,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL134959-01A1"],"award-info":[{"award-number":["1R01HL134959-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ajpath.2018.12.012","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T13:52:36Z","timestamp":1553089956000},"page":"706-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Ischemia-Reperfusion Injury in Sickle Cell Disease"],"prefix":"10.1016","volume":"189","author":[{"given":"Junaid","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity N.E.","family":"Gavins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2018.12.012_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib2","doi-asserted-by":"crossref","first-page":"e2012065","DOI":"10.4084\/mjhid.2012.065","article-title":"Sickle cell anaemia and malaria","volume":"4","author":"Luzzatto","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.ajpath.2018.12.012_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17474086.2018.1407240","article-title":"Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease","volume":"11","author":"Ansari","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways, at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib5","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajpath.2018.12.012_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2008.07473.x","article-title":"Ca2+-CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle erythrocytes","volume":"144","author":"Sabina","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2007.06794.x","article-title":"Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia?","volume":"139","author":"Vekilov","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2015.08.005","article-title":"The role of blood rheology in sickle cell disease","volume":"30","author":"Connes","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.ajpath.2018.12.012_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10739680802279394","article-title":"Sickle red cell-endothelium interactions","volume":"16","author":"Kaul","year":"2009","journal-title":"Microcirculation"},{"key":"10.1016\/j.ajpath.2018.12.012_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.hoc.2013.11.005","article-title":"Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain","volume":"28","author":"Hebbel","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ajpath.2018.12.012_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2012-11-451229","article-title":"Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins","volume":"121","author":"Schaer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib12","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2014-07-589283","article-title":"Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease","volume":"125","author":"Camus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2013-11-539718","article-title":"Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Kr\u00fcppel-like factor","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2014.00115","article-title":"Heme on innate immunity and inflammation","volume":"5","author":"Dutra","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib16","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2013-10-529982","article-title":"Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib17","doi-asserted-by":"crossref","first-page":"32844","DOI":"10.1074\/jbc.M110.146076","article-title":"Heme amplifies the innate immune response to microbial molecules through spleen tyrosine kinase (Syk)-dependent reactive oxygen species generation","volume":"285","author":"Fernandez","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2018.12.012_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10739680490278402","article-title":"The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy","volume":"11","author":"Hebbel","year":"2004","journal-title":"Microcirculation"},{"key":"10.1016\/j.ajpath.2018.12.012_bib19","first-page":"3527","article-title":"Endothelial cells in physiology and in the pathophysiology of vascular disorders","volume":"91","author":"Cines","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib20","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1182\/blood-2003-03-0693","article-title":"Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes","volume":"102","author":"Shet","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3324\/haematol.2014.119727","article-title":"Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea","volume":"100","author":"Lopes","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ajpath.2018.12.012_bib22","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion--from mechanism to translation","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6","article-title":"Pathophysiology of ischaemia-reperfusion injury","volume":"190","author":"Carden","year":"2000","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-394309-5.00006-7","article-title":"Cell biology of ischemia\/reperfusion injury","volume":"298","author":"Kalogeris","year":"2012","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib25","doi-asserted-by":"crossref","first-page":"H1723","DOI":"10.1152\/ajpheart.00553.2011","article-title":"Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures","volume":"301","author":"Sanada","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00024382-200405000-00002","article-title":"The role of the complement system in ischemia-reperfusion injury","volume":"21","author":"Arumugam","year":"2004","journal-title":"Shock"},{"key":"10.1016\/j.ajpath.2018.12.012_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0037-1613694","article-title":"Thromboinflammatory functions of platelets in ischemia-reperfusion injury and its dysregulation in diabetes","volume":"44","author":"Maiocchi","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ajpath.2018.12.012_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOT.0000000000000064","article-title":"T cells in organ ischemia reperfusion injury","volume":"19","author":"Rao","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.ajpath.2018.12.012_bib29","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1096\/fasebj.5.7.2010056","article-title":"Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia","volume":"5","author":"Lefer","year":"1991","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2018.12.012_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1172\/JCI9225","article-title":"Hypoxia\/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice","volume":"106","author":"Kaul","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2018.12.012_bib31","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.12688\/f1000research.9691.1","article-title":"Recent advances in understanding neutrophils","volume":"5","author":"Deniset","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.ajpath.2018.12.012_bib32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature15367","article-title":"Neutrophil ageing is regulated by the microbiome","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2018.12.012_bib33","first-page":"152","article-title":"Penicillin prophylaxis in children with sickle cell disease","volume":"15","author":"Cober","year":"2010","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2018.12.012_bib34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib35","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2018.12.012_bib36","doi-asserted-by":"crossref","first-page":"34101","DOI":"10.1074\/jbc.M112.394452","article-title":"Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions","volume":"287","author":"Woloszynek","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2018.12.012_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrmicro1710","article-title":"Beneficial suicide: why neutrophils die to make NETs","volume":"5","author":"Brinkmann","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib38","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.febslet.2010.06.006","article-title":"Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death","volume":"584","author":"Gupta","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ajpath.2018.12.012_bib39","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/blood-2010-08-301366","article-title":"Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S","volume":"117","author":"Gavins","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.tips.2010.04.001","article-title":"Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury?","volume":"31","author":"Gavins","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ajpath.2018.12.012_bib41","doi-asserted-by":"crossref","first-page":"e0165833","DOI":"10.1371\/journal.pone.0165833","article-title":"Inflammation in sickle cell disease: differential and down-expressed plasma levels of annexin A1 protein","volume":"11","author":"Torres","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.12.012_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041211","article-title":"Therapeutic potential of annexin A1 in ischemia reperfusion injury","volume":"19","author":"Ansari","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2018.12.012_bib43","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/ATVBAHA.110.211615","article-title":"P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease","volume":"30","author":"Polanowska-Grabowska","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib44","doi-asserted-by":"crossref","first-page":"e0177397","DOI":"10.1371\/journal.pone.0177397","article-title":"Differences of microparticle patterns between sickle cell anemia and hemoglobin SC patients","volume":"12","author":"Garnier","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.12.012_bib45","doi-asserted-by":"crossref","first-page":"e89012","DOI":"10.1371\/journal.pone.0089012","article-title":"Endothelial activation by platelets from sickle cell anemia patients","volume":"9","author":"Proenca-Ferreira","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.12.012_bib46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ajh.22274","article-title":"Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates","volume":"87","author":"Novelli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib47","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.thromres.2014.03.021","article-title":"Red blood cells and thrombin generation in sickle cell disease","volume":"133 Suppl 1","author":"Whelihan","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.ajpath.2018.12.012_bib48","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/088307389300800308","article-title":"Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage","volume":"8","author":"Broderick","year":"1993","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pbc.22242","article-title":"Acute silent cerebral infarction in children with sickle cell anemia","volume":"54","author":"Dowling","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ajpath.2018.12.012_bib51","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1542\/peds.97.6.864","article-title":"Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease","volume":"97","author":"Armstrong","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajpath.2018.12.012_bib52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/10739680701404903","article-title":"The evolving paradigm for blood cell-endothelial cell interactions in the cerebral microcirculation","volume":"14","author":"Gavins","year":"2007","journal-title":"Microcirculation"},{"key":"10.1016\/j.ajpath.2018.12.012_bib53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/path.2290","article-title":"The role of natural killer T cells in lung inflammation","volume":"214","author":"Boyton","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI10726","article-title":"Sickle cell anemia as an inflammatory disease","volume":"106","author":"Platt","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2018.12.012_bib55","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1161\/STROKEAHA.108.531632","article-title":"Apoptotic mechanisms after cerebral ischemia","volume":"40","author":"Broughton","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ajpath.2018.12.012_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12017-009-8074-1","article-title":"Leukocyte recruitment and ischemic brain injury","volume":"12","author":"Yilmaz","year":"2010","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib57","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cyto.2012.05.017","article-title":"Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia","volume":"60","author":"Hyacinth","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.ajpath.2018.12.012_bib58","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/hep.24253","article-title":"Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury","volume":"53","author":"Park","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.12.012_bib59","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1378\/chest.101.3.594","article-title":"Sepsis and coagulation: an important link","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.ajpath.2018.12.012_bib60","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/blood.V96.1.314","article-title":"Reperfusion injury pathophysiology in sickle transgenic mice","volume":"96","author":"Osarogiagbon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib61","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.hoc.2014.08.014","article-title":"Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions","volume":"28","author":"Fitzhugh","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ajpath.2018.12.012_bib62","doi-asserted-by":"crossref","first-page":"30422","DOI":"10.1038\/srep30422","article-title":"Novel HDAd\/EBV reprogramming vector and highly efficient Ad\/CRISPR-Cas sickle cell disease gene correction","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2018.12.012_bib63","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-07-2135","article-title":"Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia\/reoxygenation","volume":"102","author":"de Franceschi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib64","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00134-015-4060-2","article-title":"Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study","volume":"41","author":"Maitre","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib65","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jama.2011.235","article-title":"Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial","volume":"305","author":"Gladwin","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ajpath.2018.12.012_bib66","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Patients w-PIa: hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib67","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ajpath.2018.12.012_bib68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2010.08395.x","article-title":"A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers","volume":"151","author":"McMahon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1164\/rccm.200208-967OC","article-title":"Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?","volume":"168","author":"Morris","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia, I: subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib71","doi-asserted-by":"crossref","first-page":"e101301","DOI":"10.1371\/journal.pone.0101301","article-title":"Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia","volume":"9","author":"Wun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.12.012_bib72","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib74","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in\u00a0vivo","volume":"104","author":"Embury","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib75","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2002-02-0626","article-title":"Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin","volume":"100","author":"Matsui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib76","series-title":"Sevuparin reduces adhesion of both sickle red cells and leukocytes to endothelial cells in\u00a0vitro and inhibits vaso-occlusion in\u00a0vivo. 55th Annual American Society of Hematology Meeting [abstract], December 2013","author":"Batchvarova","year":"2013"},{"key":"10.1016\/j.ajpath.2018.12.012_bib77","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2012-11-465963","article-title":"Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson","volume":"121","author":"Field","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib78","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2018.12.012_bib79","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/1529-0131(199909)42:9<1927::AID-ANR19>3.0.CO;2-X","article-title":"Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis","volume":"42","author":"Volin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajpath.2018.12.012_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0006-8993(02)02649-5","article-title":"Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice","volume":"942","author":"Laufs","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.ajpath.2018.12.012_bib81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/cts.12005","article-title":"Effect of propranolol as antiadhesive therapy in sickle cell disease","volume":"5","author":"De Castro","year":"2012","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ajpath.2018.12.012_bib82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1081\/HEM-120035919","article-title":"Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome","volume":"28","author":"Ballas","year":"2004","journal-title":"Hemoglobin"},{"key":"10.1016\/j.ajpath.2018.12.012_bib83","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","article-title":"Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion","volume":"111","author":"Chang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib84","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/CIRCRESAHA.112.266411","article-title":"Intravenous immunoglobulins modulate neutrophil activation and vascular injury through Fc\u03b3RIII and SHP-1","volume":"110","author":"Jang","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.ajpath.2018.12.012_bib85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.23956","article-title":"Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis","volume":"90","author":"Manwani","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib86","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jth.13717","article-title":"Prothrombotic aspects of sickle cell disease","volume":"15","author":"Sparkenbaugh","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ajpath.2018.12.012_bib87","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2015-09-618553","article-title":"Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease","volume":"127","author":"Telen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib88","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/13543784.2017.1335710","article-title":"Prasugrel hydrochloride for the treatment of sickle cell disease","volume":"26","author":"Conran","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ajpath.2018.12.012_bib90","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.exphem.2008.06.014","article-title":"A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger","volume":"36","author":"Mabaera","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib91","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2002.03274.x","article-title":"Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease","volume":"116","author":"Gladwin","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib92","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib93","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2018.12.012_bib94","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2018.12.012_bib95","doi-asserted-by":"crossref","first-page":"11512","DOI":"10.1074\/jbc.M113.506121","article-title":"Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran\/basal cell adhesion molecule (Lu\/BCAM) through phosphodiesterase 4A activation","volume":"289","author":"Chaar","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2018.12.012_bib96","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib97","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease","volume":"1","author":"Field","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ajpath.2018.12.012_bib98","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1182\/blood.V97.7.1937","article-title":"Modulation of endothelial cell activation in sickle cell disease: a pilot study","volume":"97","author":"Solovey","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2018.12.012_bib99","doi-asserted-by":"crossref","first-page":"H293","DOI":"10.1152\/ajpheart.01150.2003","article-title":"Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice","volume":"287","author":"Kaul","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/asheducation-2007.1.91","article-title":"Hypercoagulability in sickle cell disease: new approaches to an old problem","author":"Ataga","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ajpath.2018.12.012_bib101","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.redox.2017.05.006","article-title":"Potential therapeutic action of nitrite in sickle cell disease","volume":"12","author":"Wajih","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.ajpath.2018.12.012_bib102","series-title":"A phase 3 study of l-glutamine therapy for sickle cell anemia and sickle \u00df0-thalassemia. 56th Annual American Society of Hematology Meeting [abstract], December 2014","author":"Niihara","year":"2014"},{"key":"10.1016\/j.ajpath.2018.12.012_bib103","series-title":"FDA Approved L-Glutamine Powder for the Treatment of Sickle Cell Disease","year":"2017"},{"key":"10.1016\/j.ajpath.2018.12.012_bib104","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944018306229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944018306229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:31:53Z","timestamp":1757694713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944018306229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0002944018306229"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2018.12.012","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ischemia-Reperfusion Injury in Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2018.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}